Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV
Authors
- Konstantinos Angelis
- Nilay Thakkar (ORCID: https://orcid.org/0000-0002-2846-5796)
- Veronica Bainbridge
- Andrew R. Tomlinson (ORCID: https://orcid.org/0000-0001-9899-0812)
- Susan Andrews (ORCID: https://orcid.org/0000-0002-5407-7201)
- Rulan Griesel (ORCID: https://orcid.org/0000-0003-3633-2878)
- Yash Gandhi (ORCID: https://orcid.org/0000-0001-7637-9617)
- Bronagh Shepherd
- Carolina Acuipil (ORCID: https://orcid.org/0009-0008-7672-3818)
- Darin Brimhall
- David Anderson (ORCID: https://orcid.org/0000-0001-9528-1340)
- Amy Pierce
- Cynthia McCoig
- Paul Benn
- Mark Baker
Institutions
- ViiV Healthcare (Spain) (ES)
- South College (US)
- ViiV Healthcare (United Kingdom) (GB)
- Glaxosmithkline (Finland) (FI)
- Thermo Fisher Scientific (United States) (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-04-26
- DOI
- https://doi.org/10.1007/s40121-025-01154-x
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79